CA1005057A - Imidazolo-as-triazines - Google Patents

Imidazolo-as-triazines

Info

Publication number
CA1005057A
CA1005057A CA189,199A CA189199A CA1005057A CA 1005057 A CA1005057 A CA 1005057A CA 189199 A CA189199 A CA 189199A CA 1005057 A CA1005057 A CA 1005057A
Authority
CA
Canada
Prior art keywords
imidazolo
triazines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA189,199A
Other languages
English (en)
Inventor
Robert W. Clarke
Alexander W. Oxford
David Hartley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allen and Hanburys Ltd
Original Assignee
Allen and Hanburys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allen and Hanburys Ltd filed Critical Allen and Hanburys Ltd
Application granted granted Critical
Publication of CA1005057A publication Critical patent/CA1005057A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA189,199A 1973-01-04 1973-12-28 Imidazolo-as-triazines Expired CA1005057A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB55373*[A GB1457873A (en) 1973-01-04 1973-01-04 Imidazotriazines

Publications (1)

Publication Number Publication Date
CA1005057A true CA1005057A (en) 1977-02-08

Family

ID=9706420

Family Applications (1)

Application Number Title Priority Date Filing Date
CA189,199A Expired CA1005057A (en) 1973-01-04 1973-12-28 Imidazolo-as-triazines

Country Status (19)

Country Link
US (1) US3941785A (en:Method)
JP (1) JPS4995994A (en:Method)
AT (1) AT336029B (en:Method)
AU (1) AU474078B2 (en:Method)
BE (1) BE809369A (en:Method)
CA (1) CA1005057A (en:Method)
CH (1) CH618170A5 (en:Method)
DE (1) DE2364076A1 (en:Method)
ES (1) ES422001A1 (en:Method)
FI (2) FI57260C (en:Method)
FR (1) FR2213058B1 (en:Method)
GB (1) GB1457873A (en:Method)
IE (1) IE38681B1 (en:Method)
IL (1) IL43872A (en:Method)
LU (1) LU69099A1 (en:Method)
NL (1) NL7400095A (en:Method)
NO (1) NO140301C (en:Method)
SE (1) SE408179B (en:Method)
ZA (1) ZA739534B (en:Method)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4107309A (en) * 1977-05-23 1978-08-15 American Cyanamid Company Substituted imidazo[1,2-d]-as-triazines
US4096257A (en) * 1977-05-23 1978-06-20 American Cyanamid Company Substituted imidazo [1,2-d]-as-triazines
US4126444A (en) * 1977-11-22 1978-11-21 American Cynamid Company Substituted imidazo (1,5-D)-as-triazin-4-ols, and herbicidal use thereof
US4308384A (en) * 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
DD244681A3 (de) * 1985-12-02 1987-04-15 Zeiss Jena Veb Carl Vorrichtung zur positionierung von enden flexibler lichtleitelemente
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
CZ301911B6 (cs) 1997-11-12 2010-07-28 Bayer Schering Pharma Aktiengesellschaft 2-Fenylsubstituované imidazotriazinony, zpusob jejich výroby, léciva tyto látky obsahující a jejich použití
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
CN1314811A (zh) 1998-08-26 2001-09-26 史密丝克莱恩比彻姆公司 治疗肺病的方法
HU229439B1 (hu) * 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
CN1633298A (zh) * 2001-05-09 2005-06-29 拜尔健康护理股份公司 2－苯基取代的咪唑三嗪酮的新用途
GB0113343D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 2
GB0113344D0 (en) 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
JP2006522127A (ja) * 2003-04-01 2006-09-28 スミスクライン ビーチャム コーポレーション イミダゾトリアジン化合物
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
AU2006299232A1 (en) * 2005-09-29 2007-04-12 Bayer Schering Pharma Aktiengesellschaft PDE inhibitors and combinations thereof for the treatment of urological disorders
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007104035A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2689638A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques

Also Published As

Publication number Publication date
ATA2374A (de) 1976-08-15
IE38681L (en) 1974-07-04
NO140301C (no) 1979-08-08
GB1457873A (en) 1976-12-08
JPS4995994A (en:Method) 1974-09-11
IL43872A0 (en) 1974-03-14
BE809369A (fr) 1974-07-03
FI793137A7 (fi) 1981-01-01
ZA739534B (en) 1974-11-27
FI57260B (fi) 1980-03-31
AU474078B2 (en) 1976-07-15
FR2213058A1 (en:Method) 1974-08-02
AT336029B (de) 1977-04-12
LU69099A1 (en:Method) 1974-04-02
US3941785A (en) 1976-03-02
DE2364076A1 (de) 1974-07-18
SE408179B (sv) 1979-05-21
ES422001A1 (es) 1976-08-01
IL43872A (en) 1979-01-31
CH618170A5 (en:Method) 1980-07-15
AU6377473A (en) 1975-06-19
FR2213058B1 (en:Method) 1977-07-01
NL7400095A (en:Method) 1974-07-08
NO140301B (no) 1979-04-30
FI57260C (fi) 1980-07-10
IE38681B1 (en) 1978-05-10

Similar Documents

Publication Publication Date Title
AU474137B2 (en) Auto-refractometer
CA1005057A (en) Imidazolo-as-triazines
CA1034948A (en) Triazolopyridazines
CA1005601A (en) Pack-bed
AU498889B2 (en) Piperidylene benzocycloheptathiophenes
AU476397B2 (en) A-cycloalkylbenzyl lactamimides
CA1031258A (en) Para-influenza-3-virus
AU476505B2 (en) Alkylbenxyl lactamimides
AU472907B2 (en) Firecheck
CA971440A (en) Headgate
CA1032172A (en) Fluoroaliphaticthiomethylsilanes
CA1015606A (en) Tyreroller
AU476386B2 (en) Dibenzocycloheptenyl lactamimides
CA1018166A (en) Benzylpyrimidines
AU471241B2 (en) Benzothiazolylureas
CA1019735A (en) Thienodiazepines
AU489559B2 (en) Amidinoureas
AU486644B2 (en) Fusebox
AU466103B2 (en) Cis-chrysanthemate
AU482866B2 (en) Unsymmetrically-substituted-s-triazines
AU487916B2 (en) Benzopyranopyridines
AU490583B2 (en) 4-aryl-5-aminoalkyl-4-oxazolin-2-ones
AU492247B2 (en) Ethenoanthracenes
AU492165B2 (en) 2-hydroxyphenyl-1-oxa-4 azaspiro-alkan-derivatives
AU478880B2 (en) 3-isoxazolidinones